

Date: 10-08- 2024

To
The General Manager
Department of Corporate Services,
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001

Scrip Code: 526139

Respected Sir / Madam,

Sub: Outcome of the Board Meeting.

This has reference to our letter dated 19th July 2024.

At a meeting of the Board of Directors of the company held on 10th August 2024 the following decisions have been taken:

- 1) The Board considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June 2024.
- 2) The Board considered and approved the Limited Review Report (Standalone & Consolidated) of the Company for the quarter ended 30th June 2024.
- 3) The Board considered and approved the extension of the date of Annual General Meeting (AGM) of the Company for the financial year 2023-24.
- 4) The Board considered and approved the appointment of M/s. Geeta Serwani & Associates, Practicing Company Secretaries as the Secretarial Auditor of the Company for the financial year 2024-2025.
- 5) The Board considered and approved the appointment of M/s. Manisha Dubey & Associates, as Internal Auditors of the Company for the financial year 2024-25.
- 6) The Board considered and approved the proposal to raise fresh funds with or without security on the assets of the Company.

The meeting commenced at 11.00 A.M and concluded at 11.45 A.M.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED



DR. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR

Encls: as above



M/S VASAVI & CO
Chartered Accountants

Limited Review report

To
The Board of Directors,
M/s TRANSGENE BIOTEK LIMITED
Hyderabad

We have reviewed the accompanying statement of unaudited standalone financial results of M/s TRANSGENE BIOTEK LIMITED for the Quarter ended 30th June 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VASAVI & CO,
Chartered Accountants
FRN 020965S

G.R.L. Vasavi

(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259



UDIN for this document is: 24249259BKHJNU1112
Place: Hyderabad
Date: 10/08/2024



M/S VASAVI & CO Chartered Accountants

Independent Auditor's Review Report On consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors,
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Transgene Biotek Ltd ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates for the quarter ended 30/06/2024 being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30/06/2024 as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



M/S VASAVI & CO Chartered Accountants

5. The Statement includes the results of the following entities:

1. Transgene Biotek HK Ltd - Subsidiary

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the interim financial results of subsidiary included in the Statement, whose interim financial results reflect total revenues of Rs. 0 million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 30 June 2024, as considered in the consolidated unaudited financial results.

**For VASAVI & CO,
Chartered Accountants
FRN 020965S**

G.R.L. Vasavi

**(CA VASAVI GOLLAPUDI)
Proprietor
MRN 249259**



UDIN for this document is: 24249259BKHJNU1112

**Place: Hyderabad
Date: 10/08/2024**

TRANSGENE
BIOTEK LIMITED

TRANSGENE BIOTEK LIMITED

Plot No:69 & 70, IDA Bollaram, Sangareddy District, Hyderabad TG 502325 IN

CIN NO: L85195TG1990PLC011065

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2024

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Unaudited)	30.06.2023 (Unaudited)	30.06.2024 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	4.92	4.50	9.99	4.92	23.49
2	Other income (net)	65.19	5.11	4.38	65.19	18.27
3	Total income (1 + 2)	70.12	9.61	14.37	70.12	41.76
4	EXPENSES					
	Cost of materials consumed	0.00	0.03	0.00	0.00	0.06
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	8.09	7.66	7.86	8.09	31.12
	Finance costs	1.73	3.23	3.23	1.73	12.91
	Depreciation and amortisation expense	2.32	2.31	2.31	2.32	9.23
	Other expenses	38.03	23.61	14.12	38.03	53.97
	Total expenses	50.18	36.84	27.52	50.18	107.30
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	19.94	-27.23	-13.15	19.94	-65.55
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	19.94	-27.23	-13.15	19.94	-65.55
8	Tax expense					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	19.94	-27.23	-13.15	19.94	-65.55
10	Other comprehensive income					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	19.94	-27.23	-13.15	19.94	-65.55
12	Earnings per equity share					
	(Equity shares, par value of Rs. 10 each)	757.70	757.70	757.70	757.70	757.70
	Basic (Rs.)	0.03	-0.04	-0.02	0.03	-0.09
	Diluted (Rs.)	0.03	(0.04)	(0.02)	0.03	(0.09)

Notes:

- 1 We received inputs from NiedlFree that a series of health supplements formulated on nano-technology platform are to be introduced into the markets within and outside India soon. In moving forward, agreements with different companies for marketing those in different regions as an ongoing process, are to be concluded accordingly.
- 2 As informed earlier, a monoclonal antibody (mAb) drug belonging to a European company has been formulated by NiedlFree and exported back in readiness for a study to be conducted in Europe. The formulated mAb drug as oral spray, is first of its kind in the world for any mAb drug, creating a new paradigm in treating cancers, arthritis etc.
- 3 Commencement of human Studies on Oral Insulin are to commence shortly on receipt of regulatory approvals.
The management has decided to raise fresh funds to repay the existing debt in the company, after getting due approvals. This
- 4 action will help not only in reactivating the projects stalled for several years but also, helps the management in taking strategic steps that benefit the shareholders.
- 5 SAT hearing took place on 9th August 2024 and has been posted for final hearing on 9th September 2024
- 6 The legal process in Switzerland to reclaim the lost GDR funds from our account is continuing.
- 7 No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- 8 The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on 10th August 2024

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 10/08/2024

Place:Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Standalone financial statements**

Other expenses		(In Lakhs)
Particulars	For the Period	ended June
	30,2024	
BSNL Fiber net	0.04	
Conveyance Expenses	0.51	
Directors sitting fee	0.15	
Legal and Professional Charges	4.16	
Miscllaneous Expenses	0.07	
Office Expenses	1.28	
Postage and Courier Expenses	0.01	
Printing and Stationary	0.00	
Rates, taxes and duties	0.01	
Telephone Expenses	0.02	
Website and Software	0.11	
Advertisement	0.14	
BSE Listing fee	3.25	
Business promotional exp	0.01	
FILM Fee- NSDI	0.10	
Annual Custody fee	1.50	
Bank charges	0.00	
Receivables Written off	26.69	
	38.03	

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao**
Managing Director**Date: 10/08/2024****Place:Hyderabad**

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2024

(In Lakhs)

Sr. No.	Particulars	Quarter Ended			Year to date figures for current period ended	Year Ended
		30.06.2024 (Unaudited)	31.03.2024 (Unaudited)	30.06.2023 (Unaudited)	30.06.2024 (Unaudited)	31.03.2024 (Audited)
1	Revenue from operations	4.92	4.50	9.99	4.92	23.49
2	Other income (net)	65.19	5.11	4.38	65.19	18.27
3	Total income (1 + 2)	70.12	9.61	14.37	70.12	41.76
4	EXPENSES					
	Cost of materials consumed	0.00	0.03	0.00	0.00	0.06
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	0.00	0.00	0.00	0.00	0.00
	Employee benefits expense	8.09	7.66	7.86	8.09	31.12
	Finance costs	1.73	3.23	3.23	1.73	12.91
	Depreciation and amortisation expense	2.32	2.31	2.31	2.32	9.23
	Other expenses	38.03	23.61	14.12	38.03	53.97
	Total expenses	50.18	36.84	27.52	50.18	107.30
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	19.94	-27.23	-13.15	19.94	-65.55
6	Exceptional item (net)	0.00	0.00	0.00	0.00	0.00
7	Profit before tax (5 - 6)	19.94	-27.23	-13.15	19.94	-65.55
8	Tax expense					
	Tax adjustments for earlier years	0.00	0.00	0.00	0.00	0.00
	Current tax	0.00	0.00	0.00	0.00	0.00
	Deferred tax	0.00	0.00	0.00	0.00	0.00
	Total tax expense	0.00	0.00	0.00	0.00	0.00
9	Profit for the year (7 - 8)	19.94	-27.23	-13.15	19.94	-65.55
10	Other comprehensive income					
	A Items that will not be reclassified subsequently to profit or loss					
	(a) Remeasurements cost of post employment benefits	0.00	0.00	0.00	0.00	0.00
	Total other comprehensive income	0.00	0.00	0.00	0.00	0.00
11	Total comprehensive income for the year (9 + 10)	19.94	-27.23	-13.15	19.94	-65.55
12	Earnings per equity share					
	(Equity shares, par value of Rs. 10 each)					
	Basic (Rs.)	757.70	757.70	757.70	757.70	757.70
	Diluted (Rs.)	0.03	-0.04	-0.02	0.03	-0.09
		0.03	(0.04)	(0.02)	0.03	(0.09)

Notes:

- We received inputs from NiedlFree that a series of health supplements formulated on nano-technology platform are to be introduced into the markets within and outside India soon. In moving forward, agreements with different companies for marketing those in different regions as an ongoing process, are to be concluded accordingly.
- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
- As informed earlier, a monoclonal antibody (mAb) drug belonging to a European company has been formulated by NiedlFree and exported back in readiness for a study to be conducted in Europe. The formulated mAb drug as oral spray, is first of its kind in the world for any mAb drug, creating a new paradigm in treating cancers, arthritis etc.
- Commencement of human Studies on Oral Insulin are to commence shortly on receipt of regulatory approvals. The management has decided to raise fresh funds to repay the existing debt in the company, after getting due approvals. This action will help not only in reactivating the projects stalled for several years but also, helps the management in taking strategic steps that benefit the shareholders.
- SAT hearing took place on 9th August 2024 and has been posted for final hearing on 9th September 2024.
- The legal process in Switzerland to reclaim the lost GDR funds from our account is continuing.
- No. of complaints pending at the beginning of the quarter - 0; received complaints during the quarter - 0.
- The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors at their meeting held on 10th August 2024.

For TRANSGENE BIOTEK LIMITED



Dr.K.Koteswara Rao
Managing Director

Date: 10/08/2024
Place:Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Consolidated financial statements**

Other expenses		(In Lakhs)
Particulars	For the Period ended June 30,2024	
BSNL Fiber net	0.04	
Conveyance Expenses	0.51	
Directors sitting fee	0.15	
Legal and Professional Charges	4.16	
Miscellaneous Expenses	0.07	
Office Expenses	1.28	
Postage and Courier Expenses	0.01	
Printing and Stationary	0.00	
Rates, taxes and duties	0.01	
Telephone Expenses	0.02	
Website and Software	0.11	
Advertisement	0.14	
BSE Listing fee	3.25	
Business promotional exp	0.01	
FILM Fee- NSDI	0.10	
Annual Custody fee	1.50	
Bank charges	0.00	
Receivables Written off	26.69	
	38.03	

For TRANSGENE BIOTEK LIMITED**Dr.K.Koteswara Rao**
Managing Director**Date: 10/08/2024****Place:Hyderabad**